



Hurcombe, J., Lay, A., Ni, L., Barrington, F., Woodgett, J. R., Quaggin, S. E., Welsh, G., & Coward, R. (2019). Podocyte GSK3 α is important for autophagy and its loss detrimental for glomerular function. *FASEB BioAdvances*, 1(8), 498-510.
<https://doi.org/10.1096/fba.2019-00011>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1096/fba.2019-00011](https://doi.org/10.1096/fba.2019-00011)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Wiley at <https://onlinelibrary.wiley.com/doi/full/10.1096/fba.2019-00011>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

RESEARCH ARTICLE

Podocyte GSK3 α is important for autophagy and its loss detrimental for glomerular function

Jennifer A. Hurcombe¹ | Abigail C. Lay¹ | Lan Ni¹ | Alexandra F. Barrington¹ |
 Jim R. Woodgett² | Susan E. Quaggin³ | Gavin I. Welsh¹ | Richard J. Coward¹

¹Bristol Renal, University of Bristol, Bristol, UK

²Lunenfeld-Tanenbaum Research Institute, Sinai Health System & University of Toronto, Toronto, ON, Canada

³Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Correspondence

Richard J. Coward, Bristol Renal, University of Bristol, Bristol, UK.
 Email: Richard.Coward@bristol.ac.uk

Funding information

Kidney Research UK; Medical Research Council, Grant/Award Number: MR/K010492/1; Canadian Institutes of Health Research; National Institute of Health; Innovative Medicines Initiative 2 Joint Undertaking, Grant/Award Number: 115974; Horizon 2020; JDRF

Abstract

Podocytes are key cells in maintaining the integrity of the glomerular filtration barrier and preventing albuminuria. Glycogen synthase kinase 3 (GSK3) is a multi-functional serine/threonine kinase existing as two distinct but related isoforms (α and β). In the podocyte it has previously been reported that inhibition of the β isoform is beneficial in attenuating a variety of glomerular disease models but loss of both isoforms is catastrophic. However, it is not known what the role of GSK3 α is in these cells. We now show that GSK3 α is present and dynamically modulated in podocytes. When GSK3 α is transgenically knocked down specifically in the podocytes of mice it causes mild but significant albuminuria by 6 weeks of life. Its loss also does not protect in models of diabetic or Adriamycin-induced nephropathy. In vitro deletion of podocyte GSK3 α causes cell death and impaired autophagic flux suggesting it is important for this key cellular process. Collectively this work shows that GSK3 α is important for podocyte health and that augmenting its function may be beneficial in treating glomerular disease.

KEYWORDS

Adriamycin nephropathy, albuminuria, diabetic nephropathy, insulin signaling

1 | INTRODUCTION

The podocyte is critical to the proper functioning of the mammalian glomerular filtration barrier and the prevention of albuminuria, a hallmark of kidney disease. Therefore, identifying signaling molecules and pathways that regulate podocyte function and which can be pharmacologically targeted is important.

Glycogen synthase kinase 3 (GSK3) is a multi-functional serine/threonine kinase which regulates a number of distinct

signaling pathways.¹ In mammals, GSK3 exists as two separate but related isoforms (α and β) with overall homology of 85% and highly conserved kinase domains (97% homology).² Because of this structural similarity, currently available GSK3 inhibitors are not isoform selective. However, there is evidence that GSK3 α and β are not entirely redundant and have different functions: GSK3 β null mice die during late embryogenesis as a result of impaired NF κ B signaling and cardiac defects^{3,4} whereas whole body GSK3 α knockout mice are

Abbreviations: AKT, protein kinase B; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; FSGS, focal segmental glomerulosclerosis; GSK3, glycogen synthase kinase 3; KO, knockout; MAPK, mitogen-activated protein kinase; PAS, periodic acid Schiff; PBS, phosphate buffered saline; PCR, polymerase chain reaction; PDGF, platelet-derived growth factor; PECAM-1, platelet endothelial cell adhesion molecule-1; STZ, streptozotocin; TBS-T, tris-buffered saline-tween 20; uACR, urinary albumin creatinine ratio; WT, wild-type; WT-1, Wilms' tumor protein.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors.

viable and interestingly, exhibit enhanced insulin sensitivity in a strain-dependent manner.⁵ Multiple cell-specific GSK3 knockout mouse models have been described and indicate that the functions of the GSK3 isoforms are cell-type dependent.⁶⁻⁹

We have recently shown that GSK3 is a crucial regulator of podocyte and kidney function and that simultaneous loss of both GSK3 isoforms in podocytes is highly detrimental.¹⁰ Developmental deletion of GSK3 results in neonatal death associated with renal failure while knockout in mature podocytes leads to a spectrum of renal disease. We also showed that prolonged pharmacological inhibition of GSK3 in rats using lithium caused significant proteinuria with evidence of focal segmental glomerulosclerosis (FSGS).¹⁰ This is consistent with reports of FSGS and renal failure in patients on long-term lithium therapy for conditions such as bipolar disorder.^{11,12} In contrast, a number of recent studies suggest that partial pharmacological inhibition of GSK3 as well as specific genetic knockout of the β isoform in podocytes can be beneficial in a number of experimental glomerular disease models including diabetic nephropathy, lupus nephritis and Adriamycin nephropathy.¹³⁻¹⁷ However, the role of podocyte GSK3 α has received little consideration and it is not known whether this isoform has a specific role in podocyte homeostasis or if its loss can also have a podocyte protective effect.

Given our interest in podocyte insulin signaling¹⁸ and the suggestion that specifically inhibiting GSK3 α could enhance cellular insulin sensitivity we were keen to study the specific role of this GSK3 isoform in the podocyte. We therefore developed a mouse and podocyte cell model to do this.

We show here that reduced podocyte expression of GSK3 α does not attenuate albuminuria in streptozotocin (STZ) diabetes or Adriamycin nephropathy models in mice. Moreover, near complete knockout of GSK3 α in conditionally immortalized podocytes did not result in improved insulin sensitivity or attenuation of Adriamycin induced injury. Conversely, we found that loss of podocyte GSK3 α is mildly detrimental and reveal a role for this isoform in maintaining podocyte autophagic flux.

2 | MATERIALS AND METHODS

2.1 | Murine insulin stimulation

Following an overnight fast, wild-type mice were given an intraperitoneal injection of insulin (Novo Nordisk) at 1 unit/kg body weight (6 nmol/L). Mice were sacrificed after 10 minutes and the kidneys snap frozen in liquid nitrogen.

2.2 | Immunofluorescence staining of kidney sections

Frozen kidneys were sectioned at 5 μ m. Sections were blocked in phosphate buffered saline (PBS) containing 3%

bovine serum albumin (BSA) and 0.3% triton X-100 for 1 hour, then incubated with primary antibodies overnight at 4°C (pGSK3 α 1:100; pGSK3 β 1:100; nephrin 1:300; Wilm's tumor protein [WT-1] 1:200). Following three PBS rinses, sections were incubated with fluorophore-conjugated secondary antibodies (Life Technologies) for 1 hour at room temperature. Tissues were imaged using a Leica DM2000 microscope and micrographs taken with Leica Application Suite. Image analysis was performed with ImageJ; all images were contrast enhanced using the same parameters.

2.3 | Insulin and Adriamycin stimulation of cultured podocytes

Conditionally immortalized mouse podocyte cell lines were used as previously described.^{19,20} Cells were serum starved for 4 hours then stimulated with insulin (Novo Nordisk) at 10 nM and 100 nM/L for 10 minutes.

For the Adriamycin injury model, cells were incubated with Adriamycin (Sigma) at the concentrations indicated for 24 hours.

2.4 | Western blotting

Cultured cells were lysed in radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors (Sigma). Ten to thirty micrograms of protein was resolved by electrophoresis then transferred to a polyvinylidene difluoride membrane (Millipore). Membranes were blocked in TRIS-buffered saline with 0.1% tween 20 and 5% BSA for 1 hour then incubated overnight with primary antibody at a dilution of 1:1000. Membranes were washed before incubation with horseradish peroxidase conjugated secondary antibody (Sigma). Immunoreactive bands were visualized using Clarity ECL Western blotting substrate (Biorad) on a GE AI600 imager. Densitometry was performed using ImageJ software.

2.5 | Mouse models

Mice in which exon two of GSK3 α has been flanked by loxP sites⁵ were crossed with podocin Cre mice²¹ to generate podocyte-specific GSK3 α knockdown animals from embryonic day 12 (podGSK3 α KD mice).

Diabetes was induced in mice at 6 weeks of age by intraperitoneal injection of STZ (Sigma) at 50 mg/kg body weight for five consecutive days. Mice injected with an identical volume of citrate buffer served as sham controls.

Adriamycin nephropathy was induced in mice at 8-10 weeks of age by a single tail vein injection of Adriamycin (Sigma) at 12 mg/kg body weight. These were studied for 2 weeks.

For STZ and Adriamycin models, mice were backcrossed for four generations onto a DBA/2J strain background. Both sexes were studied.

Transgenic mouse work was carried out in accordance with the University of Bristol's institutional guidelines and procedures approved by the United Kingdom (UK) Home Office in accordance with UK legislation.

2.6 | Podocyte primary culture

Glomeruli were isolated from podGSK3 α KD and littermate control mice following dynabead perfusion as described previously.²² Glomeruli were plated out in Roswell Park Memorial Institute (RPMI) 1640 media supplemented with 10% fetal bovine serum and 5% penicillin/streptomycin and incubated at 37°C. After 6 days, primary podocytes were harvested by trypsinization and cells were passed through a 40 μ m cell strainer to remove glomeruli.

2.7 | End point PCR

Mouse genotyping was performed using 5 \times PCRbio hs taq DNA polymerase (Insight) and the following primers:

Cre forward GTGCAACTTGAATAACCGGAAATGG
Cre reverse AGAGTCATCCTTACCGCCGTAAATCAAT
GSK3 α forward CCCCCACCAAGTGATTCTCACTGCTA
GSK3 α reverse AACATGAAATTCCGGGCTCCAACCTCTAT

RNA was isolated from podocyte primary cells using an Rneasy kit (Qiagen) and cDNA synthesized using a high capacity RNA to cDNA kit (ThermoFisher Scientific). Primers used were:

WT-1 forward GAGAGCCAGCCTACCATCC
WT-1 reverse GGGTCCTGGTGTGTTGAAGCAA
Platelet endothelial cell adhesion molecule-1 (PECAM) forward CAAGCAAAGCAGTGA
PECAM reverse AGCAGGACAGGTCCAACAAC
Platelet-derived growth factor (PDGF) forward ACTTCTGTTGCTACACGAAGC
PDGF reverse CGGTTGAGTCAGTGGAGTCC

2.8 | Urinary albumin and creatinine measurements

Albumin and creatinine levels in mouse urine were measured using a mouse-specific albumin ELISA (Bethyl) and creatinine companion kit (Exocell), following the manufacturers' methodology.

2.9 | Periodic acid Schiff staining

Kidneys were fixed in 10% buffered neutral formalin, further processed and paraffin embedded. Three micrometer sections were cut and stained using a Periodic acid Schiff staining kit

(Sigma) according to the manufacturers' instructions. Tissues were imaged using a Leica DN2000 microscope and micrographs taken using Leica Application Suite software. Image analysis was performed using ImageJ; all images were contrast enhanced using the same parameters.

Glomerulosclerosis was scored for each glomerulus as follows: 0 = normal glomeruli; 1 = up to 25% involvement; 2 = 25%-50% involvement; 3 = 50%-75% involvement; 4 = over 75% involvement. The glomerulosclerosis index was calculated according to the formula $([1 \times N1] + [2 \times N2] + [3 \times N3] + [4 \times N4]) / (N0 + N1 + N2 + N3 + N4)$, where Nx is the number of glomeruli with each given score.

2.10 | Lentiviral transduction of a conditionally immortalized GSK3 α floxed podocyte cell line

Kidneys were isolated from GSK3 $\alpha^{fl/fl}$ mice and used to make a temperature-sensitive SV40 conditionally immortalized podocyte cell line as described previously.¹⁹ Cells were cultured at 33°C and when 50% confluent were transduced with a lentivirus expressing Cre recombinase as described previously.¹⁰ Transduction was in RPMI media with hexadimethrine bromide (Sigma) at 4 μ g/mL and the virus used at a multiplicity of infection of 1. Following a 24-hour incubation, the lentivirus was removed and replaced with fresh media. Cells were thermo-switched to 38°C and incubated for a further 7 days before imaging and protein extraction.

To determine ciGSK3 α KO cell number, cells were washed three times in PBS, the nuclei stained with Hoechst (Sigma) at 1 μ g/mL and imaged using an IN Cell analyzer 2200 (GE Healthcare) and data analyzed using IN Cell analyzer Developer software (GE Healthcare).

2.11 | Determination of podocyte number

Immunofluorescent analysis of mouse kidney sections was carried out as described above using a WT-1 antibody (Abcam). 4',6-diamidino-2-phenylindole (DAPI) was used to counterstain nuclei. ImageJ software was used to count WT-1 positive nuclei and expressed as a percentage of the total number of DAPI stained cells per glomerulus.

2.12 | Antibodies

Antibodies were obtained from Cell Signalling Technology: (pGSK3 α [Ser 21] #9316; pGSK3 β [Ser 9] #9323; total GSK3 α/β #5676; total GSK3 α #9338; pAKT [Ser 473] #4060; total AKT #4691; P-p44/42 MAPK #4370; p44/42 MAPK #4695); Acris (Nephrin #BP5030); Sigma (β -actin clone AC-15; GAPDH #G8795); Merck Millipore (WT-1



clone 6F-H2, used for western blotting), Abcam (WT-1 #89901) and Genetex (SV40 T antigen #134377).

2.13 | Statistics

Statistical analysis was performed using GraphPad Prism software. When comparing two groups *t* tests were used. When comparing more than two groups analysis of variance (ANOVA) was used. Statistical tests used and *n* numbers are shown in figure legends. Data are presented as the mean and error bars represent the standard error of the mean. $P < 0.05$ was deemed statistically significant.

3 | RESULTS

3.1 | Both GSK3 α and GSK3 β are phosphorylated in podocytes of murine glomeruli and in murine conditionally immortalized podocytes in response to insulin

We initially established that both GSK3 α and GSK3 β were expressed and dynamically regulated in the podocyte by studying wild-type mice challenged with insulin after an overnight fast (Figure 1A,B). This revealed the rapid phosphorylation, and hence inactivation, of GSK α , at serine 21, and GSK3 β , at serine 9, in the kidney. Both isoforms were phosphorylated in glomeruli and tubules. However, within the glomerulus phosphorylated GSK3 isoforms were highly enriched in the podocyte cell fraction. This was particularly clear for GSK3 α as revealed by 3D reconstructive imaging of insulin treated glomeruli (Video S1). Western blotting of conditionally immortalized podocytes confirmed these phosphorylation findings in vitro (Figure 1C,D). Preliminary dose-response experiments showed that our mouse podocyte cell line activated the PI3K pathway in response to insulin at 1 nmol/L but this was more apparent at higher doses (Figure S1). Therefore, in subsequent experiments, cells were stimulated with insulin at 10 and 100 nmol/L. Although greater than the levels of insulin present in diabetic patients, 10-100 nmol/L is the standard dose used in the literature to elucidate insulin driven signaling pathways.²³⁻²⁸ Our in vivo studies were performed with insulin doses of 6 nmol/L.

3.2 | Generation of podocyte-specific GSK3 α knockdown mice

To study the effect of GSK3 α deletion in podocytes we generated transgenic mice by crossing GSK3 α floxed mice with mice expressing Cre recombinase under the control of a podocin promoter to confer podocyte specificity (Figure 2A). Genotypes of the progeny were confirmed using polymerase chain reaction (PCR) (Figure 2B). Primary culture podocytes were also generated from podGSK3 α KD mice and

Cre negative control littermates and knockdown of GSK3 α determined using Western blotting (Figure 2C, D). GSK3 α expression was reduced by 50% in podGSK3 α KD mice while GSK3 β expression remained unchanged. We analyzed the purity of our primary cultures using sensitive PCR analysis of cDNA derived from the primary cultures. This revealed some expression of PECAM and PDGF (markers of glomerular endothelial and mesangial cells) in two of the Cre negative control samples, likely due to a small amount of glomerular contamination of the primary podocytes. However, in the GSK3 α KD cells the cell population appeared to be predominantly of podocyte origin (Figure 2E). Finally, podocyte knockdown of GSK3 α was confirmed by co-staining kidney sections from podGSK3 α KD and Cre negative control mice with total GSK3 α and nephrin antibodies (Figure 2F).

3.3 | Podocyte-specific knockdown of GSK3 α does not ameliorate the progression of diabetic nephropathy in an STZ model of diabetes

Previous studies have shown improved insulin sensitivity and glucose handling in skeletal muscle cells of total body GSK3 α knockout mice.⁵ Since podocytes are insulin responsive cells,²⁹ we sought to determine whether podocyte-specific deletion of GSK3 α would ameliorate the progression of diabetic nephropathy in a mouse model of diabetes by improving insulin sensitivity. Diabetes was induced in podGSK3 α KD mice and Cre negative control littermates by STZ administration at 6 weeks of age. Successful induction of diabetes was confirmed by measuring blood glucose at 4 weeks and hyperglycemia as well as body weight was identical in knockdown and control groups (Figure 3A,B). Urinary albumin creatinine ratio (uACR) was increased at 20 weeks in both knockdown and control groups after STZ induction with evidence of mild glomerulosclerosis on histological examination, but no statistical differences were observed between them (Figure 3C,D) showing that the progression of diabetic nephropathy was not attenuated by podocyte GSK3 α knockdown.

3.4 | Knockdown of GSK3 α does not improve insulin sensitivity with respect to PI3 kinase signaling

Podocyte GSK3 α knockdown did not have a protective effect on the progression of STZ-induced diabetic nephropathy but it is possible that this result was due to incomplete knockdown of GSK3 α in our transgenic mouse model. To determine whether an increased level of GSK3 α knockdown would be more effective in enhancing insulin sensitivity at a cellular/molecular level, we developed a temperature-sensitive conditionally immortalized cell line from podocytes isolated from GSK3 α floxed mice (Figure 4A). This cell line switched off the SV40





FIGURE 1 GSK3 α as well as β is phosphorylated in the podocyte in the murine glomerulus and in murine conditionally immortalized podocytes. (A, B) Immunofluorescent analysis of serine 21 phosphorylated GSK3 α (A) and serine 9 phosphorylation of GSK3 β (B) performed in mice that were fasted overnight and then given insulin (6 nmol/L) for 10 min. Podocyte-specific phosphorylation of GSK3 (green) is shown by co-localization with Nephryn (magenta)(white demonstrates co-localization) arrowed in magnified images, scale bar = 25 μ m. (C, D) Insulin increases inhibitory phosphorylation of GSK3 in conditionally immortalized murine podocytes. Representative blot (C) and densitometry shown (D). Unpaired *t* test, **P* < 0.05; ***P* < 0.01, *n* = 3 experiments

FIGURE 2 Generation of podocyte-specific GSK3 α knockdown mice. A, Breeding strategy used to generate podGSK3 α KD mouse model showing deletion of GSK3 α exon 2 in podGSK3 α KD mice. B, Gel of end point polymerase chain reaction (PCR) products used to identify genotypes of podGSK3 α KD mice. C, Western blot of podocyte primary culture cells from podGSK3 α KD and littermate control mice. D, Densitometry of blot showing fold change of GSK3 α and GSK3 β levels normalized to GAPDH expression. Unpaired *t* test, ***P* < 0.01. podGSK3 α KD podocytes have reduced expression of GSK3 α . All primary podocytes express the podocyte marker WT-1. E, Gel of end point PCR analysis of cDNA derived from podGSK3 α KD and littermate control mice with WT-1, PECAM and PDGF primers. Mouse kidney cDNA was used as a positive control. F, Immunofluorescent analysis of total GSK3 α in podGSK3 α KD and Cre negative control mice including co-staining with the podocyte marker protein nephryn. Scale bar = 50 μ m ($\times 20$); 75 μ m ($\times 100$)







FIGURE 3 Podocyte-specific knockdown of GSK3 α does not ameliorate the progression of diabetic nephropathy in an streptozotocin (STZ) model of diabetes. A, Body weights in STZ-treated (+STZ) and citrate buffer-injected (-STZ) podGSK3 α KD and control mice. One way ANOVA not significant, control mice $n = 7$, podGSK3 α KD mice $n = 9$, citrate controls $n = 3$ for each genotype. B, Blood glucose measurements showing successful induction of STZ-induced diabetes at 4 wk. STZ treated (+STZ); citrate controls (-STZ). One way ANOVA, *** $P < 0.001$. C, Urinary albumin:creatinine in STZ-treated (+STZ) and citrate buffer-injected (-STZ) mice at 20 wk. One way ANOVA not significant, control mice $n = 7$, podGSK3 α KD mice $n = 9$, citrate controls $n = 3$ for each genotype. D, Representative periodic acid Schiff staining and glomerulosclerosis index of STZ-treated mice (+STZ) and citrate controls (-STZ) at 20 wk. Mild glomerulosclerosis observed in STZ-treated animals (arrowed) but no difference between podGSK3 α KD mice controls, one way ANOVA, * $P < 0.05$, >30 glomeruli per mouse analyzed, three mice per group.

transgene following differentiation at the non-permissive temperature of 38°C and expressed typical podocyte marker proteins (Figure 4B). Using this in vitro system, we were able to generate podocytes with >95% knockdown of GSK3 α (Figure 4C). Both conditionally immortalized GSK3 α knock-out podocytes (ciGSK3 α KO) and non-transduced control cells responded to insulin stimulation, significantly increasing

phosphorylation of AKT at serine 473 and exhibiting similar levels of glucose uptake (Data not shown). However, there was no difference between control and knockout cells indicating that even near-total knockdown of GSK3 α expression did not improve podocyte insulin sensitivity (Figure 4D).

We also studied the dynamic regulation of mitogen-activated protein kinase (MAPK) ex-vivo in the podocytes of

FIGURE 4 Knockdown of GSK3 α does not improve insulin sensitivity with respect to PI3 kinase signalling. A, Development of ciGSK3 α KO cells. Isolation of primary podocytes, conditional immortalization using SV40 construct and excision of GSK3 α using lentiviral-delivered Cre recombinase. B, ciGSK3 α KO cells express markers of differentiated podocytes after thermoswitching. C, Western blot and densitometry of ciGSK3 α KO cells showing >95% knockdown of GSK3 α . Unpaired t test, ** $P < 0.01$. D, Western blot and densitometry of ciGSK3 α KO and control cells stimulated with 10 and 100 nmol/L insulin. No differences in phosphorylated AKT (pAKT) serine 473 or phosphorylated 44/42MAPK (p44/42MAPK) between the two groups. ANOVA with Tukey's post hoc test, ** $P < 0.01$. $n = 3$ experiments. E, Immunofluorescent analysis of p44/42 MAPK performed in podGSK3 α KD and Cre negative control mice that were fasted overnight and given insulin (6 nmol/L) for 10 min. Podocyte-specific phosphorylation of MAPK is shown by co-localization with nephrin (shown in white in merged images). Scale bar = 50 μ m ($\times 20$); 75 μ m ($\times 100$). MAPK, mitogen-activated protein kinase






FIGURE 5 Podocyte-specific knockout of GSK3 α is not protective in in vivo and in vitro Adriamycin injury models. A, Body weights of Adriamycin-treated mice. (B) Urinary albumin:creatinine in Adriamycin-treated mice showing increased albuminuria in both podGSK3 α KD and control mice at 1 and 2 wk. t test ** $P < 0.01$. C, Representative images of ciGSK3 α KO and non-transduced control cells treated with Adriamycin for 24 h. D, Cell survival is identical in ciGSK3 α KO and control cells treated with Adriamycin for 24 h. $n = 3$ experiments

podGSK3 α KD and Cre negative control mice challenged with insulin after an overnight fast (Figure 4E). This confirmed that podGSK3 α KD mice were able to phosphorylate MAPK in response to insulin but there did not appear to be any enhancement of this phosphorylation compared with podocyte GSK3 α sufficient animals.

3.5 | Podocyte-specific knockdown of GSK3 α is not protective in in vivo and in vitro Adriamycin injury models

In light of previous studies showing the beneficial effects of both pharmacological inhibition of GSK3 and podocyte-specific genetic GSK3 β deletion in doxorubicin injury models,¹⁴⁻¹⁶ we hypothesized that isoform-specific knockdown of GSK3 α in podocytes might have similar protective effects. Adriamycin nephropathy, a model of podocyte injury, glomerulosclerosis and fibrosis³⁰ was induced in podGSK3 α KD mice by a single tail vein injection at 12 mg/kg body weight when mice were 8-10 weeks of age and mice were monitored for 2 weeks before sacrifice. uACR was significantly increased at 2 weeks

but no differences in albuminuria or body weight were apparent between podGSK3 α KD mice and control littermates (Figure 5A,B).

To determine whether the increased GSK3 α knockdown achieved in ciGSK3 α KO cells would improve Adriamycin podocyte injury in vitro, we incubated cells with Adriamycin at 0, 0.25, 0.5 and 1 μg/mL for 24 hours. Both ciGSK3 α KO and control cells looked unhealthy and were dying at an Adriamycin dose of 1 μg/mL (Figure 5C). Determination of cell number at Adriamycin concentrations of 0-1 μg/mL using the non-biased IN CELL computer-based analyzer, confirmed that GSK3 α deletion had no beneficial impact on cell survival (Figure 5D).

3.6 | Podocyte GSK3 α knockdown is detrimental causing increased uACR in vivo and increased cell death with impaired autophagic flux in ciGSK3 α KO cells

Although podGSK3 α KD mice did not exhibit any overt phenotypic differences to controls with regard to body

weight and kidney histology (Figure S2A,C), we observed a small but significantly increased basal uACR in podGSK3 α KD mice at 6 weeks of age (Figure 6A; Figure S2B). We sought to further investigate the apparent detrimental effect of GSK3 α reduction in podocytes by performing in vitro studies on ciGSK3 α KO cells. Although we did not see any evidence of podocyte loss in our mouse model (Figure S2D), a cell survival assay performed 7 days after gene knockout using our in vitro model showed a 25% rate of cell death in ciGSK3 α KO cells when compared to controls (Figure 6B). GSK3 α has been found to be a critical regulator of autophagy, and its loss in a mouse global knockout model results in accelerated senescence in multiple tissues when aged.³¹ Previous studies have shown the importance of autophagy for podocyte homeostasis^{32–36} so we assessed autophagy in ciGSK3 α KO cells. We observed that the polyubiquitin-binding protein p62, which is degraded by autophagy, was increased in ciGSK3 α KO cells (Figure 6C,D). However, although a higher basal level of p62 is suggestive of reduced autophagy in ciGSK3 α KO cells, autophagy is a dynamic process and should be measured as a flux event. This can be represented by the difference in the amount of LC3II (which correlates with autophagosome number) in ciGSK3 α KO and control cells in the presence or absence of the lysosomal inhibitor bafilomycin A1.¹⁹ We did not observe a clear band corresponding to LC3I but it is known that the sensitivity of immunoblotting for LC3I is much lower than for LC3II and that differences in LC3II accumulation between samples is the most accurate way to assess autophagy by Western blot.¹⁹ Differences in the levels of p62 before and after bafilomycin exposure indicate the amount of p62 that would normally be degraded by autophagy in each cell type. Using this approach, we found that the levels of p62 degradation (Figure 6E) and LC3II accumulation (Figure 6F) were significantly reduced in ciGSK3 α KO cells indicative of impaired autophagic flux. We also assessed if enhancing autophagy in ciGSK3 α KO cells by co-incubating with the mTOR inhibitor Rapamycin would affect cell survival but did not find this to be the case (Figure S3).

4 | DISCUSSION

We show here that in contrast to previous research indicating that podocyte-specific genetic knockout of GSK3 β has a beneficial effect in models of kidney disease; podocyte ablation of GSK3 α is not similarly protective. Our findings indicate that conversely, its loss is mildly detrimental revealing a role for the α isoform in podocyte homeostasis.

Mice with global knockout of GSK3 α have been shown to have enhanced insulin sensitivity⁵ albeit in a strain-dependent manner.⁸ We initially hypothesized that genetic knockdown

of podocyte GSK3 α might attenuate albuminuria in an STZ-induced model of diabetes due to increased podocyte insulin sensitivity. However, this was not the case.

In our animal model podocyte GSK3 α expression was reduced by only approximately 50%, which we think was because our podocin Cre driver lost some of its Cre recombinase potency as a result of epigenetic silencing due to a high frequency of CpG dinucleotides.³⁷ It is therefore possible that our in vivo results were due to incomplete gene knockdown. However it is important to remember that pharmacological GSK3 inhibitors cause a reduction in activity of approximately 25%⁷ which suggests that our findings are clinically relevant. The limited level of GSK3 α knockdown in vivo led us to develop ciGSK3 α KO podocytes with >95% gene knockout. However, we found that even this near complete knockdown of GSK3 α in cultured podocytes did not elicit any increase in insulin sensitivity, consistent with our in vivo observations. Similarly, we did not observe any beneficial effect of podocyte GSK3 α knockdown in in vivo and in vitro Adriamycin injury models contrary to results reported using podocyte-specific GSK3 β knockout mice.^{13,14,38} Our results suggest that GSK3 α does not represent a potential target for augmentation of podocyte insulin signaling and that it is the reduction in GSK3 β and not GSK3 α activity that is responsible for the beneficial anti-albuminuric and podocyte protective effects of pharmacological GSK3 inhibitors.^{13,15,16,39} We have recently shown that some GSK3 enzyme activity is critically important for podocyte and kidney function both developmentally and in maturity. When both mammalian GSK3 isoforms (α and β) are lost genetically, or sufficiently suppressed pharmacologically, it causes a severe phenotype.¹⁰ This is also the case when the GSK3 gene is lost in similar cells in other species including the nephrocyte of *Drosophila*.¹⁰

Because GSK3 inhibitors are not isoform selective, future work to elucidate the beneficial and detrimental signaling pathways differentially regulated by GSK3 α and β may facilitate the identification of new drug targets for the treatment of albuminuric kidney disease lacking the deleterious side effects that result from excessive suppression of GSK3 activity.

Interestingly, we noted a mild but significant increase in albuminuria in podGSK3 α KD mice and further investigated this apparent detrimental effect in vitro using ciGSK3 α KO cells. We observed that 7 days after near complete knockout of GSK3 α , podocytes were more susceptible to cell death providing further evidence that GSK3 α has a role in podocyte homeostasis. Although we did not find evidence of similar podocyte loss in podGSK3 α KD mice, this may be due to the much lower degree of gene knockdown in vivo (approximately 50%) compared with the >95% GSK3 α loss in ciGSK3 α KO cells. Most GSK3 research has concentrated on the β isoform or the use of pharmacological GSK3 inhibitors and there




FIGURE 6 Podocyte GSK3 α knockdown is detrimental causing increased urinary albumin creatinine ratio in vivo and increased cell death with impaired autophagic flux in ciGSK3 α KO cells. A, Urinary albumin:creatinine is increased in podGSK3 α KD mice. Unpaired t test, $*P < 0.05$. $n = 12$ –13 mice per group. B, Cell survival assay showing 25% cell death in ciGSK3 α KO podocytes 7 d after transduction when compared with untransduced control cells or Cre lenti transduced wild-type podocytes. ANOVA with Tukey's post hoc test, $**P < 0.01$. wild-type cells, $n = 3$, GSK3 α floxed cells $n = 6$ experiments. C, Representative blots of ciGSK3 α KO and control cells treated with bafilomycin A1 for 4 h. D, Densitometry showing increased basal expression of p62 in ciGSK3 α KO cells. Unpaired t test, $*P < 0.05$ $n = 3$. E, Level of p62 degradation represented by the difference in p62 levels \pm bafilomycin A1 in ciGSK3 α KO and control cells. Unpaired t test, $*P < 0.05$ $n = 4$. F, Accumulation of LC3BII represented by the difference in LC3BII levels \pm bafilomycin A1 in ciGSK3 α KO and control cells. Unpaired t test, $*P < 0.05$ $n = 3$

are few reports in the literature describing the effects of specific loss of GSK3 α . The original study describing the generation of whole body GSK3 α knockout mice⁵ found

that such mice were viable with no adverse phenotype, however subsequently it has been shown that male mice lacking GSK3 α in their testicular germ cells are sterile.⁴⁰

Additionally, a further recent elegant study of global GSK3 α knockout mice has revealed that detrimental effects of GSK3 α knockout become apparent as mice age. These mice had a reduced life span along with multiple age-related pathologies attributable to a decreased level of autophagy.³¹ Autophagy, a conserved process that delivers proteins and damaged organelles to lysosomes for degradation and turnover⁴¹ has been shown to be important in podocyte homeostasis. In common with other terminally differentiated cell types, podocytes have a high level of autophagy under basal conditions³² and impairment of this process has been implicated in podocyte damage associated with aging,^{35,42,43} diabetic nephropathy,³⁴ mitochondrial dysfunction and FSGS.³³ Conversely, enhancement of autophagic activity has a protective effect in models of glomerular disease.^{36,44} As global GSK3 α knockout has been found to impair autophagy in multiple organ systems, we surmised that GSK3 α knockout podocytes might also be autophagy deficient. We found this to be the case and that ciGSK3 α KO podocytes had increased basal levels of p62 and reduced autophagic flux consistent with the cell death and increased albuminuria observed in our in vitro and in vivo podocyte GSK3 α knockout models. We also assessed if impaired autophagy was directly linked to cell death in our knockout models by co-incubating GSK3 α knockout cells with the mTOR inhibitor Rapamycin but this did not have an effect in the short term. Going forward it will be of interest to significantly age the podocyte-specific GSK3 α mice, ideally using a Cre driver that is resistant to epigenetic degradation which has now been generated⁴⁵ to assess for podocyte loss, glomerular disease and autophagocytic function. We speculate these would be abnormal.

In conclusion we have shown that partial or near-total suppression of podocyte GSK3 α is not protective in models of glomerular disease; its loss is, in fact, detrimental and is associated with impaired autophagic flux. This reveals a novel role for GSK3 α in maintenance of podocyte function by promoting autophagy. Strategies to maintain or increase GSK3 α activity may therefore represent a potential therapeutic target in albuminuric kidney disease.

ACKNOWLEDGEMENTS

This work was funded by Kidney Research UK, the Medical Research Council, which funds RJC with a Senior Clinical Research Fellowship (MR/K010492/1), Canadian Institutes of Health Research and the National Institute of Health. Latterly it was supported by funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA with JDRF.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Studies were conceived by JAH, RJC, JRW, GIW and SEQ. The majority of in vitro and in vivo work was performed by JAH with help from ACL and AFB. LN made the conditionally immortalized floxed GSK3 α podocyte cell line.

REFERENCES

1. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. *Trends Biochem Sci.* 2004;29:95-102.
2. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. *The EMBO journal.* 1990;9:2431-2438.
3. Hoefflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3 β in cell survival and NF-kappaB activation. *Nature.* 2000;406:86-90.
4. Kerkela R, Kockeritz L, Macaulay K, et al. Deletion of GSK-3 β in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. *J Clin Invest.* 2008;118:3609-3618.
5. MacAulay K, Doble BW, Patel S, et al. Glycogen synthase kinase 3 α -specific regulation of murine hepatic glycogen metabolism. *Cell Metab.* 2007;6:329-337.
6. Hurtado DE, Molina-Porcel L, Carroll JC, et al. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. *J Neurosci.* 2012;32:7392-7402.
7. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. *Front Mol Neurosci.* 2011;4:40.
8. Patel S, Macaulay K, Woodgett JR. Tissue-specific analysis of glycogen synthase kinase-3 α (GSK-3 α) in glucose metabolism: effect of strain variation. *PLoS ONE.* 2011;6:e15845.
9. Zhou W, Chen L, Paul J, et al. The effects of glycogen synthase kinase-3 β in serotonin neurons. *PLoS ONE.* 2012;7:e43262.
10. Hurcombe JA, Hartley P, Lay AC, et al. Podocyte GSK3 is an evolutionarily conserved critical regulator of kidney function. *Nat Commun.* 2019;10:403.
11. Hansen HE, Hestbech J, Olsen S, Amdisen A. Renal function and renal pathology in patients with lithium-induced impairment of renal concentrating ability. *Proc Eur Dial Transplant Assoc.* 1977;14:518-527.
12. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. *J Am Soc Nephrol.* 2000;11:1439-1448.
13. Zhou S, Wang P, Qiao Y, et al. Genetic and pharmacologic targeting of glycogen synthase kinase 3 β reinforces the Nrf2 antioxidant defense against podocytopathy. *J Am Soc Nephrol.* 2016;27:2289-2308.
14. Li C, Ge Y, Dworkin L, Peng A, Gong R. The beta isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy. *J Pathol.* 2016;239:23-35.
15. Wang Z, Bao H, Ge Y, Zhuang S, Peng A, Gong R. Pharmacological targeting of GSK3 β confers protection against podocytopathy

- and proteinuria by desensitizing mitochondrial permeability transition. *Br J Pharmacol*. 2015;172:895-909.
16. Xu W, Ge Y, Liu Z, Gong R. Glycogen synthase kinase 3 β dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy. *Am J Pathol*. 2014;184:2742-2756.
 17. Xu W, Ge Y, Liu Z, Gong R. Glycogen synthase kinase 3 β orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion. *J Biol Chem*. 2015;290:1348-1363.
 18. Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. *Cell Metab*. 2010;12:329-340.
 19. Saleem MA, O'Hare MJ, Reiser J, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. *J Am Soc Nephrol*. 2002;13:630-638.
 20. Hale LJ, Hurcombe J, Lay A, et al. Insulin directly stimulates VEGF-A production in the glomerular podocyte. *Am J Physiol Renal Physiol*. 2013;305:F182-F188.
 21. Eremina V, Wong MA, Cui S, Schwartz L, Quaggin SE. Glomerular-specific gene excision in vivo. *J Am Soc Nephrol*. 2002;13:788-793.
 22. Takemoto M, Asker N, Gerhardt H, et al. A new method for large scale isolation of kidney glomeruli from mice. *Am J Pathol*. 2002;161:799-805.
 23. Garvey WT, Olefsky JM, Marshall S. Insulin induces progressive insulin resistance in cultured rat adipocytes. Sequential effects at receptor and multiple postreceptor sites. *Diabetes*. 1986;35:258-267.
 24. Gavin JR 3rd, Roth J, Neville DM Jr, de Meyts P, Buell DN. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. *Proc Natl Acad Sci USA*. 1974;71:84-88.
 25. Gonzalez M, Boer U, Dickel C, et al. Loss of insulin-induced inhibition of glucagon gene transcription in hamster pancreatic islet alpha cells by long-term insulin exposure. *Diabetologia*. 2008;51:2012-2021.
 26. Kim B, McLean LL, Philip SS, Feldman EL. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. *Endocrinology*. 2011;152:3638-3647.
 27. Mayer CM, Belsham DD. Palmitate attenuates insulin signaling and induces endoplasmic reticulum stress and apoptosis in hypothalamic neurons: rescue of resistance and apoptosis through adenosine 5' monophosphate-activated protein kinase activation. *Endocrinology*. 2010;151:576-585.
 28. Okabayashi Y, Maddux BA, McDonald AR, Logsdon CD, Williams JA, Goldfine ID. Mechanisms of insulin-induced insulin-receptor downregulation. Decrease of receptor biosynthesis and mRNA levels. *Diabetes*. 1989;38:182-187.
 29. Coward RJ, Welsh GI, Yang J, et al. The human glomerular podocyte is a novel target for insulin action. *Diabetes*. 2005;54:3095-3102.
 30. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. *Nephrology (Carlton, Vic.)*. 2011;16:30-38.
 31. Zhou J, Freeman TA, Ahmad F, et al. GSK-3 α is a central regulator of age-related pathologies in mice. *J Clin Invest*. 2013;123:1821-1832.
 32. Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. *J Clin Invest*. 2010;120:1084-1096.
 33. Kawakami T, Gomez IG, Ren S, et al. Deficient autophagy results in mitochondrial dysfunction and FSGS. *J Am Soc Nephrol*. 2015;26:1040-1052.
 34. Tagawa A, Yasuda M, Kume S, et al. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. *Diabetes*. 2016;65:755-767.
 35. Weide T, Huber TB. Implications of autophagy for glomerular aging and disease. *Cell Tissue Res*. 2011;343:467-473.
 36. Xin W, Li Z, Xu Y, et al. Autophagy protects human podocytes from high glucose-induced injury by preventing insulin resistance. *Metab, Clin Exp*. 2016;65:1307-1315.
 37. Cohen-Tannoudji M, Vandormael-Pournin S, Drezen J, Mercier P, Babinet C, Morello D. lacZ sequences prevent regulated expression of housekeeping genes. *Mech Dev*. 2000;90:29-39.
 38. Li C, Ge Y, Peng A, Gong R. The redox sensitive glycogen synthase kinase 3 β suppresses the self-protective antioxidant response in podocytes upon oxidative glomerular injury. *Oncotarget*. 2015;6:39493-39506.
 39. Paeng J, Chang JH, Lee SH, et al. Enhanced glycogen synthase kinase-3 β activity mediates podocyte apoptosis under diabetic conditions. *Apoptosis*. 2014;19:1678-1690.
 40. Bhattacharjee R, Goswami S, Dudiki T, et al. Targeted disruption of glycogen synthase kinase 3A (GSK3A) in mice affects sperm motility resulting in male infertility. *Biol Reprod*. 2015;92:65.
 41. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol*. 2018;19:349-364.
 42. Lenoir O, Tharaux PL, Huber TB. Autophagy in kidney disease and aging: lessons from rodent models. *Kidney Int*. 2016;90:950-964.
 43. Fougeray S, Pallet N. Mechanisms and biological functions of autophagy in diseased and ageing kidneys. *Nat Rev Nephrol*. 2015;11:34-45.
 44. Zeng C, Fan Y, Wu J, et al. Podocyte autophagic activity plays a protective role in renal injury and delays the progression of podocytopathies. *J Pathol*. 2014;234:203-213.
 45. Koehler S, Brahler S, Braun F, et al. Construction of a viral T2A-peptide based knock-in mouse model for enhanced Cre recombinase activity and fluorescent labeling of podocytes. *Kidney Int*. 2017;91:1510-1517.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Hurcombe JA, Lay AC, Ni L, et al. Podocyte GSK3 α is important for autophagy and its loss detrimental for glomerular function. *FASEB BioAdvances*. 2019;1:498-510. <https://doi.org/10.1096/fba.2019-00011>